Blood, blood components, plasma, and plasma products

Side Effects of Drugs Annual

Volumn 23, Issue , 2000, Pages 359-367

  Eijkhout, H W ^a   van Aken, W G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35648989113     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(00)80039-2     Document Type: Article

References (69)

1. Anonymous Blood products (manufactured)—reporting adverse reactions WHO Pharm Newslett 5/6 1998 6 7
2. Scott MG Kucik DF Goodnough LT Monk TG Blood substitutes: evolution and future applications Clin Chem 43 1997 1724 1731
3. Spence RK Perfluorocarbons in the twenty-first century: clinical applications as transfusion alternatives Artif Cells Blood Substitutes Immobilization Biotechnol 23 1995 367 380
4. Flaim SF Hazard DR Hogan J Peters RM Characterization and mechanism of side-effects of Oxygent HT in swine Biomater Artif Cells Immobilization Biotechnol 19 1991 383 385
5. Anonymous Albumin (human) batches withdrawn: increase in aluminium levels WHO Newsletter 9/10 1998 1
6. Anonymous Albumin and plasma protein fraction-safety concerns WHO Newsletter 9/10 1998 6
7. Anonymous Albumin (human) batches withdrawn: increase in aluminium levels WHO Newsletter 1/2 1999 1
8. Milgrom H Shortage of intravenous immunoglobulin Ann Allergy Asthma Immunol 81 1998 97 100
9. Stangel M Hartung HP Marx P Gold R Intravenous immunoglobulin treatment of neurological autoimmune disease J Neurol Sci 153 1998 203 214
10. Hern S Harman K Bhogal BS Black MM A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin Clin Exp Dermatol 23 1998 185 188
11. Enk AH Knop J Adjuvante Therapie von Pemphigus vulgaris und Pemphigus foliaceus mit intravenösen Immunoglobulinen Hautartz 49 1998 774 776
12. Colonna L Cianchini G Frezzolini A De Pita O Di Lella G Puddu P Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy Br J Dermatol 138 1998 1102 1103
13. Silver RM Managment of idiopathic thrombocytopenic purpura in pregnancy Clin Obstet Gynecol 41 1998 436 448
14. Bagdasarian A Tonetta S Harel W Mamidi R Uemura Y IVIG adverse reactions: potential role of cytokines and vasoactive substances Vox sang 74 1998 74 82
15. Machkhas H Harati Y Side effects of immuno-suppressant therapies used in neurology Neurol Clin 16 1998 171 188
16. Attout H Mallet H Desmurs H Berthier S Gil H De Waziéres B Dupond JL Méningite aseptique au course d'un traitement par immunoglobulines intraveineuses a très faibles doses Rev Med Interne 19 1998 140 141
17. Jolles S Hill H Management of aseptic meningitis secondary to intravenous immunoglobulin Br Med J 316 1998 936
18. Finkel AG Howard JF Douglas Mann J Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications Headache 38 1998 317 321
19. Hazouard E Sauvagnac X Corcia Ph Legras A Dequin PF Ginies G Accident vasculaire transitoire possiblement lié aux immunoglobulines intraveneineuses Presse Med 27 1998 161
20. Tsiouris J Tsiouris N Hemiplegia as a complication of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin J Pediatr 133 1998 717
21. Choudhry VP Mahapatra M Kashyap R Immunoglobulin therapy in immunohematological disorders Indian J Pediatr 65 1998 681 690
22. Stangel M Müller M Marx P Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disorders Eur Neurol 40 1998 173 174
23. Wills AJ Unsworth DJ A practical approach to the use of intravenous immunoglobulin in neurological disease Eur Neurol 39 1998 3 8
24. Lee YC Woodfield DG Douglas R Clinical usage of intravenous immunoglobulins in Auckland NZ Med J 111 1998 48 50
25. Jolles S Hughes J Whittaker S Dermatological uses of high-dose intravenous immunoglobulin Arch Dermatol 134 1998 80 86
26. Stahl M Schifferi JA The renal risks of high-dose intravenous immunoglobulin treatment Nephtol Dial Transplant 13 1998 2182 2185
27. Ahsan N Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy J Nephrol 11 1998 157 161
28. Howse M Bindoff L Carmichael A Facial vasculitic rash associated with intravenous immunoglobulin Br Med J 317 1998 1291
29. Lawn N Wijdicks EFM Burritt MF Intravenous immune globulin and pseudohyponatremia New Eng J Med 339 1998 632
30. Roberts HR Clinical experience with activated factor VII: focus on safety aspects Blood Coagul Fibrinolyses 9 Suppl 1 1998 S115 S118
31. Key NS Aledort LM Beardsley D Cooper HA Davignon G Ewenstein BM Gilchrist GS Gill JC Glader B Hoots WK Kisker CT Lusher JM Rosenfield CG Shapiro AD Smith H Taft E Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors Thromb Haemost 80 1998 912 918
32. White G Shapiro A Ragni M Garzone P Goodfellow J Tubridy K Courter S Clinical evaluation of recombinant factor IX Semin Hematol 35 Suppl 2 1998 33 38
33. Bolton-Maggs PHB The management of factor XI deficiency Haemophilia 4 1998 683 688
34. Butler AC Tait RC Management of oral anticoagulant-induced intracranial haemorrhage Blood Rev 12 1998 35 44
35. Ferguson JJ Kereiakes DJ Adgey AAJ Fox KAA Hillegass WB Pfisterer M Vassanelli C Safe use of platelet GP IIb/IIIa inhibitors Am Heart J 135 1998 S77 S89
36. Tengborn L Hansson S Fasth A Lübeck P-O Berg A Ljung R Anaphylactoid reactions and nephrotic syndrome—a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report in the outcome in two brothers Haemophilia 4 1998 854 859
37. Dharnidharka VR Takemoto C Ewenstein BM Rosen S Harris HW Membranous glomerulonephritis and nephrosis post factor IX infusion in hemophilia B Pediatr Nephrol 12 1998 654 657
38. Dioun AF Ewenstein BM Geha RS Schneider LC IgE-mediated allergy and desensitization to factor IX in hemophilia B J Allergy Clin Immunol 102 1998 113 117
39. Hoots K Canty D Clotting factor concentrates and immune function in haemophilic patients Haemophilia 4 1998 704 713
40. Giangrande PLF Hepatitis in haemophilia Haematol 103 1998 1 9
41. Sumazaki R Yamada-Osaki M Kajiwara Y Shirahata A Matsui A Transfusion transmitted virus Lancet 352 1998 1308 1309
42. Fujiwara T Iwata A Iizuka H Tanaka T Okamoto H Transfusion transmitted virus Lancet 352 1998 1310
43. Dietrich W Incidence of hypersensitivity reactions Ann Thorac Surg 65 Suppl 6 1998 S60 S64
44. Faught C Wells P Fergusson D Laupacis A Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature Transfus Med Rev 12 1998 206 225
45. Wakeen M Zimmerman SW Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis Am J Kidney Dis 32 1998 488 493
46. Aufricht C Marik JL Ettenger RB Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction Pediatr Nephrol 12 1998 10 13
47. Barosi G Marchetti M Liberato NL Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia Br J Cancer 78 1998 781 787
48. Csáki C Ferencz T Schuler D Borsi JD Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumors Eur J Cancer 34 1998 364 367
49. Dalton WS Anemia in multiple myeloma and its management Cancer Control 5 1998 S46 S50
50. Veys N Use and abuse of erythropoietin Tijdschr Geneeskd 54 1998 1315 1322
51. Cazzola M How and when to use erythropoietin Curr Opin Hematol 5 1998 103 108
52. Beguin Y A risk-benefit assessment of epoetin in the management of anaemia associated with cancer Drug Saf 19 1998 269 282
53. MacKinnon GE Singla D Epoetin alfa in chronic renal failure P&T 23 1998 437 446
54. Ohira N Takasugi K Takasugi N Yorioka N Ito T Kushihata S Takemasa A Dose escalation induces tolerance to side-effects of erythropoietin in a patient with dialysis anaemia: case report J Int Med Res 26 1998 102 105
55. Kaufman JS Reda DJ Fye CL Goldfarb DS Henderson WG Kleinman JG Vaamonde CA Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis New Engl J Med 39 1998 578 583
56. Goodnough LT Guidelines for the treatment of preoperative anaemia with epoetin Biodrugs 10 1998 183 191
57. Cumming MN Sharkey IM Sharp J Plant ND Coulthard MG Subcutaneous erythropoietin alpha (Eprex) is more painful than erythropoietin beta (Recormon) Nephrol Dial Transplant 13 1998 817
58. Veys N Dhondt A Lameire N Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta Clin Nephrol 49 1998 41 44
59. Kang D-K Yoon K-I Han D-S Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients Nephrol Dial Transplant 13 1998 2877 2883
60. Ifudu O Dawood M Homel P Erythropoietin-induced elevation in blood pressure is immediate and dose dependent Nephron 79 1998 486 487
61. Tuskahara H Hori C Tsuchida S Hiraoka Fujisawa K Mayumi M Role of endothelin in erythropoietin-induced hypertension in rats Nephron 79 1998 499 500
62. Beccari M Erythropoietin-induced epilepsy in hemodialysis patients? Nephron 78 1998 354
63. Latini GM Rosati E Transient neutropenia may be a risk of treating neonates with high doses of recombinant erythropoietin Eur J Pediatr 157 1998 443 444
64. Buemi M Allegra A Corica F Cavallaro G Aloisi C Pettinato G Frisina N Rapid and transient lymphocytopenia after i.v. administration of high doses of human recombinant erythropoietin Hematol Pathol Mol Hematol 11 1998 13 17
65. Rigalleau V Blanchetier V Aparicio M Baillet L Sneed J Dabadie H Gin H Erythropoietin can deteriorate glucose control in uraemic non-insulin-dependent diabetic patients Diabetes Metab 24 1998 52 65
66. Brown JA Nehra A Erythropoietin-induced recurrent veno-occulusive priapism associated with end-stage renal disease Urology 52 1998 328 330
67. Ten Bokkel Huinink WW De Swart CAM Van Toorn DW Morack G Breed WPM Hillen HFP Van Der Hoeven JJM Reed NS Fairlamb DJ Chan SYT Godfey KA Kristensen GB Van Tinteren H Ehmer B Controlled multicentre study the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy Med Oncol 15 1998 174 182
68. Ramsey G Hematopoietic growth factors and transfusion medicine Transfus Med Rev 12 1998 195 205
69. Archimbaud E Thomas X Thrombopoietic factors potentially useful in the treatment of acute leukemia Leuk Res 22 1998 1155 1164